Satellos Bioscience Inc. — Investor Relations & Filings
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing regenerative small molecule therapeutics for degenerative muscle diseases, primarily Duchenne muscular dystrophy (DMD). The company's core mission is to restore the body's natural ability to regenerate muscle, addressing the failure of muscle repair inherent in these conditions. Satellos utilizes a novel approach rooted in muscle biology, focusing on restoring the asymmetric division of muscle stem cells (satellite cells), a process disrupted by the absence of dystrophin in DMD. Their strategy involves targeting the AAK1 protein to reactivate the natural repair mechanism. The lead therapeutic candidate, SAT-3247, is currently advancing into a Pediatric Phase 2 clinical study for DMD.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Notice.pdf | 2024-09-19 | English | |
| News release - English.pdf | 2024-09-05 | English | |
| 52-109F2 - Certification of interim filings - CEO (E).pdf | 2024-08-12 | English | |
| 52-109F2 - Certification of interim filings - CFO (E).pdf | 2024-08-12 | English | |
| Interim MD&A - English.pdf | 2024-08-12 | English | |
| Interim financial statements/report – English.pdf | 2024-08-12 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 13751309 | Notice.pdf | 2024-09-19 | English | ||
| 30676737 | News release - English.pdf | 2024-09-05 | English | ||
| 30496439 | 52-109F2 - Certification of interim filings - CEO (E).pdf | 2024-08-12 | English | ||
| 30496421 | 52-109F2 - Certification of interim filings - CFO (E).pdf | 2024-08-12 | English | ||
| 30496454 | Interim MD&A - English.pdf | 2024-08-12 | English | ||
| 30496469 | Interim financial statements/report – English.pdf | 2024-08-12 | English | ||
| 30497070 | News release - English.pdf | 2024-08-12 | English | ||
| 13742706 | News release - English.pdf | 2024-07-11 | English | ||
| 30312609 | News release - English.pdf | 2024-07-02 | English | ||
| 30026889 | Other.pdf | 2024-05-15 | English | ||
| 30026867 | Other.pdf | 2024-05-15 | English | ||
| 30027144 | Report of voting results.pdf | 2024-05-15 | English | ||
| 30028729 | News release - English.pdf | 2024-05-14 | English | ||
| 30031479 | 52-109F2 - Certification of interim filings - CEO (E).pdf | 2024-05-14 | English | ||
| 30031476 | 52-109F2 - Certification of interim filings - CFO (E).pdf | 2024-05-14 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Satellos Bioscience Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/48203/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=48203 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=48203 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=48203 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 48203}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Satellos Bioscience Inc. (id: 48203)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.